<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355978</url>
  </required_header>
  <id_info>
    <org_study_id>CP-00-0031</org_study_id>
    <nct_id>NCT01355978</nct_id>
  </id_info>
  <brief_title>Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>PRIDE</acronym>
  <official_title>Acceptability, Comfort, and Exercise Tolerance Using a Non-invasive Ventilation System in Patients With Moderate-to-Severe COPD (PRIDE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breathe Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Breathe Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When using the Breathe Technologies Ventilation System during simulated activities of daily
      living (ADLs), Subjects with moderate-to-severe chronic obstructive pulmonary Disease (COPD)
      will be comfortable and report acceptability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study was to evaluate the Breathe Technologies Ventilator System
      with regard to subject acceptability, comfort, and effect on exercise and activities of daily
      living tolerance.

      Primary Hypothesis:

        1. When using the Breathe Technologies Ventilation System during simulated activities of
           daily living (ADL), Subjects with moderate-to-severe COPD will be comfortable and report
           acceptability.

           Secondary Hypotheses:

        2. When using the Breathe Technologies Ventilation System during simulated ADLs, Subjects
           with moderate-to-severe COPD will experience tolerable dyspnea as measured using the
           Borg Dyspnea Score (BDS) and a visual analog Comfort Scale (VACS).

        3. Subjects will prefer using the Breathe Technologies Ventilation System over standard
           oxygen therapy during exertion and during ADLs after using the ventilator therapy for
           five days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device Tidal Volume</measure>
    <time_frame>Periodically over six hours x 5 days</time_frame>
    <description>Evaluate the mean test volume for three activity levels. Subjects completed five consecutive, 6-hour clinic days in which the NIOV system was worn continuously while at rest, during activities of daily living (ADLs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Preference</measure>
    <time_frame>At conclusion of subject's participation (up to two weeks)</time_frame>
    <description>5-point Likert Scale completed at the end or the 5-day study period
- Preference Scale: 5 = Max preference (Prefer to use the test device), 1 = Min preference (Do not prefer to use the test device)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Device-related Adverse Events</measure>
    <time_frame>Continuous from Study Day 2 through Study Day 6</time_frame>
    <description>Any adverse events reported during he study period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Airflow Obstruction, Chronic</condition>
  <condition>Chronic Obstructive Airway Disease</condition>
  <condition>Chronic Obstructive Lung Disease</condition>
  <arm_group>
    <arm_group_label>Noninvasive Open Ventilation System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Portable noninvasive open ventilator &amp; nasal interface.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Noninvasive Open Ventilation System</intervention_name>
    <description>Noninvasive ventilation system</description>
    <arm_group_label>Noninvasive Open Ventilation System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have participated and completed the NOVEL 1 or NOVEL 2 studies.

          -  Be 21-80 years of age (inclusive) at time of informed consent.

          -  Require nasal oxygen of ≥ 2 LPM during exertion, and ≥ 1 LPM at rest.

          -  Exhibit dyspnea and have lung disease process dominated by COPD per the Study
             Investigator.

          -  Have a self-reported MMRC Dyspnea Score ≥ 2 on a scale of 0-4.

          -  Have spirometric evidence of COPD with an FEV1 of &lt; 50% predicted and FEV1/FVC &lt; 0.70,
             measured within the last 6 months (GOLD stage III and IV).

          -  Have a resting respiratory rate of less than or equal to 30 bpm.

          -  Be fluent in reading and speaking the English language.

          -  Be able to clearly communicate and to indicate a self-assessment of dyspnea and/or
             fatigue.

          -  Be willing and able to participate in, and to complete all required study procedures,
             including the ability to pull an E-sized oxygen cylinder.

          -  Report having a smoking history of ≥ 10 pack-years.

          -  Provide written informed consent to participate in the study.

        Exclusion Criteria:

        Subject must NOT meet any of the following criteria, or they will be excluded from study
        participation:

          -  Be a current tobacco smoker

          -  Have a history of pneumothorax in last 2 years.

          -  Have a history of severe, giant bullae.

          -  Have a history of unstable angina

          -  Reports the onset of cardiac arrhythmia(s) within the past 7 days.

          -  Report having serious epistaxis within the last 10 days.

          -  Have a history of severe pulmonary hypertension and/or NYHA Stage III and IV
             decompensated heart failure.

          -  Reports symptoms of acute COPD exacerbation within the past 48 hours.

          -  Have been discharged from the hospital within 30 days of screening for infection or
             acute illness or COPD exacerbation.

          -  Have a prescription or history of requiring &gt; 8 LPM oxygen during exertion.

          -  Have a history of serious allergic airways disease (e.g., high eosinophil count or
             elevated IgE).

          -  Report or have evidence of LVEF &lt; 30 %

          -  Have a BMI &gt; 40

          -  Have a history of thoracotomy, sternotomy, major cardiopulmonary intervention (e.g.,
             lung resection, open heart surgery), or any procedure 6 months before study entry
             likely to cause instability of pulmonary status.

          -  Have a history of lung disease unrelated to smoking that affects oxygenation or
             survival.

          -  Is participating in another intervention study or have participated within 90 days of
             enrollment.

          -  Have endobronchial valves or other bronchial tree implants such as stents.

          -  Have a disease or condition expected to cause death, inability to perform procedures
             for the trial, or inability to comply with the therapy.

          -  Have a history of intolerance to oxygen therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Kops, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Muir Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn McCabe, RRT, RCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharp HealthCare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Muir Health</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKay-Dee Hospital Center</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <results_first_submitted>March 7, 2015</results_first_submitted>
  <results_first_submitted_qc>August 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2016</results_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Noninvasive Open Ventilation System</title>
          <description>Portable noninvasive open ventilator &amp; nasal interface.
Noninvasive Open Ventilation System: Noninvasive ventilation system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Adult subjects with chronic obstructive lung disease.</population>
      <group_list>
        <group group_id="B1">
          <title>Noninvasive Open Ventilation System</title>
          <description>Portable noninvasive open ventilator &amp; nasal interface. Noninvasive Open Ventilation System used during activities of daily living.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Device Tidal Volume</title>
        <description>Evaluate the mean test volume for three activity levels. Subjects completed five consecutive, 6-hour clinic days in which the NIOV system was worn continuously while at rest, during activities of daily living (ADLs).</description>
        <time_frame>Periodically over six hours x 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Noninvasive Open Ventilation System</title>
            <description>Portable noninvasive open ventilator &amp; nasal interface.
Noninvasive Open Ventilation System: Noninvasive ventilation system</description>
          </group>
        </group_list>
        <measure>
          <title>Device Tidal Volume</title>
          <description>Evaluate the mean test volume for three activity levels. Subjects completed five consecutive, 6-hour clinic days in which the NIOV system was worn continuously while at rest, during activities of daily living (ADLs).</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Preference</title>
        <description>5-point Likert Scale completed at the end or the 5-day study period
- Preference Scale: 5 = Max preference (Prefer to use the test device), 1 = Min preference (Do not prefer to use the test device)</description>
        <time_frame>At conclusion of subject's participation (up to two weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Noninvasive Open Ventilation System</title>
            <description>Portable noninvasive open ventilator &amp; nasal interface.
Noninvasive Open Ventilation System: Noninvasive ventilation system</description>
          </group>
        </group_list>
        <measure>
          <title>Device Preference</title>
          <description>5-point Likert Scale completed at the end or the 5-day study period
- Preference Scale: 5 = Max preference (Prefer to use the test device), 1 = Min preference (Do not prefer to use the test device)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Device-related Adverse Events</title>
        <description>Any adverse events reported during he study period.</description>
        <time_frame>Continuous from Study Day 2 through Study Day 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Noninvasive Open Ventilation System</title>
            <description>Portable noninvasive open ventilator &amp; nasal interface.
Noninvasive Open Ventilation System: Noninvasive ventilation system</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Device-related Adverse Events</title>
          <description>Any adverse events reported during he study period.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Continuously for 1 week, starting a screening visit through end of study (Day 6).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Noninvasive Open Ventilation System</title>
          <description>Portable noninvasive open ventilator &amp; nasal interface.
Noninvasive Open Ventilation System: Noninvasive ventilation system</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <description>Subject SH011 reported being SOB following exercising on treadmill. SOB resolved after discontinuing exercise. No intervention was required.</description>
                <counts group_id="E1" events="18" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <description>Subject JM008 reported being SOB during performance of simulated activity of daily living (vacuuming). SOB resolved quickly when ADL was stopped. No other intervention was required.</description>
                <counts group_id="E1" events="18" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>For Subject JM003, a mild skin rash was noted on the finger on which the pulse oximeter probe was attached. The probe was relocated and the rash resolved without intervention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard J. Morishige, MS, RRT</name_or_title>
      <organization>Clinical Research Consuting</organization>
      <phone>510-606-0374</phone>
      <email>rjmorishige@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

